Mineralys Therapeutics, Inc. (MLYS)
Nasdaq: MLYS · Pharmaceutical Preparations · Radnor, PA · filing with the SEC since 2022
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Report filed | Mar 12, 2026 | Feb 12, 2025 | Mar 21, 2024 | Mar 15, 2023 |
| Research and development | 132,009 | 168,581 | 70,361 | 26,250 |
| General and administrative | 38,595 | 23,822 | 14,296 | 5,229 |
| Total operating expenses | 170,604 | 192,403 | 84,657 | 31,479 |
| Operating income | -170,604 | -192,403 | -84,657 | -31,479 |
| Interest income (expense), net | 15,953 | 14,588 | 12,756 | 1,676 |
| Other income (expense), net | 0 | 5 | 3 | · |
| Total non-operating income (expense) | 15,953 | 14,593 | 12,759 | 1,680 |
| Income tax expense | 0 | · | · | · |
| Net income | -154,651 | -177,810 | -71,898 | -29,799 |
| Earnings per share, basic | -2.29 | -3.66 | -1.99 | -5.77 |
| Earnings per share, diluted | -2.29 | -3.66 | -1.99 | -5.77 |
| Weighted average shares, basic | 67,656,355 | 48,539,795 | 36,188,254 | 5,167,296 |
| Weighted average shares, diluted | 67,656,355 | 48,539,795 | 36,188,254 | 5,167,296 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest income (expense), net interest earned less interest paid, outside the business
us-gaap:InterestIncomeExpenseNonoperatingNetOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding